J. Goldman & CO LP Arvinas, Inc. Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding ARVN
# of Institutions
229Shares Held
68.4MCall Options Held
226KPut Options Held
285K-
Vanguard Group Inc Valley Forge, PA7.01MShares$181 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$174 Million7.19% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$162 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.85MShares$99.7 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.78MShares$72 Million1.09% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $1.38B
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...